Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: AP Photos
The White House has withdrawn the nomination of physician and presidential adviser Dr. Heidi Overton to lead the Food and Drug Administration (FDA), ending her bid for the top regulatory post just a day before a scheduled Senate committee vote.
Overton, the third reported candidate considered for the position after former FDA Commissioner Marty Makary's departure in May, was nominated by President Donald Trump in August. Trump had praised her as a “ROCKSTAR” when announcing his choice.
“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy wrote on X shortly after the withdrawal.
A senior administration official told Axios that Overton “lacks the support on the Hill to move forward with her confirmation.”
Also read: Meet Heidi Overton: Trump Set to Nominate White House Adviser to Lead FDA
The nomination faced growing resistance from Republican members of the 21-member Senate committee. Overton needed the support of all 12 Republicans to advance, assuming all 11 Democrats voted against her.
Several Republican senators had not committed to supporting her, including Cassidy, Susan Collins and Lisa Murkowski. The uncertainty left the White House struggling to secure the votes needed ahead of the November 18 committee hearing.
Cassidy, however, maintained that Overton was close to securing enough support. Calling the withdrawal “odd,” he said he had been having productive conversations with senators and believed she could have cleared both the committee and the full Senate.
Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation
Overton faced opposition over her positions on vaccine policy, abortion medication and vaping, exposing divisions among Republicans and the MAHA movement.
Vaccine policy: Cassidy questioned her role in Trump's efforts to change childhood vaccine recommendations, including splitting the combined measles, mumps and rubella (MMR) vaccine. Overton maintained that the MMR vaccine was safe and effective and said she would follow FDA safety requirements.
Mifepristone restrictions: Anti-abortion groups and Republican Sen. Josh Hawley questioned her commitment to tightening restrictions on mifepristone, the abortion pill. Meanwhile, Republican senators Susan Collins and Lisa Murkowski raised concerns about her strong anti-abortion positions.
Flavoured vapes: Overton faced criticism for her role in the administration's authorisation of fruit-flavoured e-cigarettes. Opponents even launched a campaign using the label “Heidi Vaperton” to urge senators to reject her nomination.
MAHA backlash: Some supporters of Robert F. Kennedy Jr.'s Make America Healthy Again movement accused Overton of being too close to corporate and agricultural interests. Former White House adviser Calley Means alleged that her decisions on glyphosate and flavoured vapes conflicted with Kennedy's agenda.
Overton is a physician and former deputy director of the White House Domestic Policy Council. Before her nomination, she worked at the conservative think tank America First Policy Institute, where she eventually led its Health Policy Center.
She received her medical degree from the University of New Mexico, completed general surgery training at Johns Hopkins University and pursued clinical investigation research training at the Johns Hopkins Bloomberg School of Public Health.
She also served during Trump's first administration before joining the think tank.
Overton was involved in several prominent health policy initiatives under the current administration, including efforts to redesign the food pyramid, overhaul childhood vaccine recommendations and negotiate prescription drug pricing deals.
The withdrawal leaves the FDA without a Senate-confirmed commissioner. Acting Commissioner Kyle Diamantas has been leading the agency since Makary resigned in May.
The administration is now considering potential replacements, including Republican Senator Roger Marshall of Kansas, according to Reuters. No new nominee has been formally announced.
Credit: AI image
Amid growing research in vaccination for different cancers, an experimental cancer vaccine cut the risk of death by 41% in patients with acute myeloid leukemia (AML) in a late-stage clinical trial.
Showing promise in treating the aggressive blood cancer, the findings have given hope to patients whose cancer has returned after treatment and those who have limited options.
The vaccine, called galinpepimut-S (GPS), is being developed by US-based pharma company SELLAS Life Sciences. Results from the Phase 3 REGAL trial showed that patients who received the vaccine lived longer than those given the next best available treatment.
Acute myeloid leukemia is an aggressive blood cancer that begins in the bone marrow, the soft tissue inside bones responsible for producing blood cells. It develops when abnormal immature blood cells multiply rapidly and interfere with the production of healthy red blood cells, white blood cells and platelets.
Common symptoms include persistent fatigue, fever, frequent infections, easy bruising, unusual bleeding and breathlessness.
Treatment usually involves chemotherapy, specific medicines in eligible patients and in some cases, stem-cell transplantation. AML can return after treatment, making it difficult to achieve remission.
The trial involved 126 patients who had achieved remission after treatment but were unable to undergo a stem-cell transplant.
According to the findings, the vaccine reduced the risk of death by 41%. Patients receiving GPS had a median overall survival of 24 months, compared to 14.7 months among those receiving standard treatment. The results also showed a hazard ratio of 0.59 and a p-value of 0.035.
SELLAS plans to discuss the findings with the US Food and Drug Administration (FDA), preparing to submit an application for approval in the first half of 2027.
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Unlike preventive vaccines, GPS is a therapeutic cancer vaccine. It is developed to help immune system identify and destroy residual cancer cells in the body after treatment.
The vaccine targets a protein called Wilms' Tumour 1 (WT1), which is found in more than 95% of people with AML, according to Memorial Sloan Kettering Cancer Center (MSK), where the vaccine was developed.
GPS contains synthetic peptides, which are short chains of amino acids derived from the WT1 protein. These peptides help the immune system to produce specialised T cells that recognise and attack cancer cells carrying WT1.
In simple terms, the vaccine trains the immune system to identify leftover cancer cells that may be too small to detect through routine testing but could eventually cause cancer recurrence.
Unlike personalised cancer vaccines that are manufactured using an individual patient's tumour, GPS is an off-the-shelf vaccine that can be used in multiple patients.
GPS was generally tolerated well in the Phase 3 trial as no safety concerns were identified. Most side effects were mild to moderate. Reactions at injection sites were among the most commonly reported side effects.
The company, however, has only announced topline results. The detailed findings from the trial's secondary endpoints related to relapse-free and leukemia-free survival, will be presented at a future medical conference.
If the findings are supported by regulatory authorities, GPS could become a new treatment option for patients whose AML has relapsed and those who cannot opt for a stem-cell transplant.
Credit: AI image
The United States is not the only country to lose its measles elimination status this year. Mexico and Bolivia have also lost the status after the highly contagious virus continued spreading for more than 12 months, according to the Pan American Health Organization (PAHO).
The decision was formally announced on November 17, 2026 by PAHO's independent Regional Monitoring and Re-Verification Commission, which reviewed measles data from 47 countries and territories across the Americas.
The United States had maintained its measles elimination status since 2000, while Mexico and Bolivia had also previously interrupted sustained local transmission. The latest development marks a setback in efforts to control a disease that can be prevented through vaccination.
The announcement comes as measles cases continue to rise across the region. As of November 13, 2026, the Americas had reported 58,213 confirmed cases and 82 deaths, compared with 12,806 cases during the same period in 2025.
Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC
According to PAHO, a country loses its measles elimination status when the same measles virus genotype and lineage circulates continuously within its borders for at least 12 months. This indicates that the virus has re-established endemic transmission rather than appearing only through isolated cases imported from other countries.
According to PAHO, the sustained transmission periods in the three countries began on different dates:
Losing elimination status does not mean that measles is spreading everywhere within these countries. It means that the same virus lineage has continued circulating locally for at least a year.
The Americas had previously lost its regional measles elimination status in November 2025, after Canada reported to have sustained transmission for more than 12 months. The region had first eliminated measles in 2016 and regained that achievement in 2024 after stopping transmission in Venezuela and Brazil.
Also read: US Loses Measles Elimination Status After 26 Years: What Does It Mean?
After PAHO's announcement, US Health and Human Services Secretary Robert F. Kennedy Jr and Centers for Disease Control and Prevention (CDC) Director Dr Erica Schwartz issued separate statements.
Kennedy said the administration would continue working to control outbreaks and restore the country's elimination status.
"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," he said in a statement. He also expressed his support for vaccination, adding, "I continue to recommend MMR vaccination as the most effective way to prevent measles."
Kennedy attributed gaps in childhood immunisation to disruptions during the COVID-19 pandemic which affected routine vaccination programmes in the US and other countries.
He also said that approximately $100 million in additional CDC funding has been provided since August to strengthen measles prevention and outbreak response. The funding is intended to support state and local health departments, improve surveillance and help close vaccination gaps.
CDC Director Dr Schwartz said the loss of the designation would not change the agency's approach to controlling the disease.
"The measles elimination designation is not what protects Americans. Vaccination does. We know where transmission is occurring and we've invested $100 million in state and local health departments to reach those communities," she said.
"Losing a designation doesn't mean we abandon an evidence-based approach. It means we remain focused on stopping outbreaks."
Also read: RFK Jr's Vaccine Controversy: What His Samoa Trip Has To Do With 83 Measles Deaths
The latest PAHO figures highlight the scale of the resurgence. The region recorded more than four times as many confirmed measles cases by November 13, 2026 as during the corresponding period in 2025.
Mexico has reported more than 13,900 confirmed cases so far in 2026, the highest annual total since the 1989-90 epidemic. The US has recorded more than 5,400 cases and 10 deaths, its highest in more than 35 years. Bolivia has reported more than 100 cases.
Amid the resurgence, a CDC report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
Measles is among the most contagious infectious diseases. One infected person can transmit the virus to as many as 18 people who are susceptible to infection.
The disease typically causes fever, cough, a runny nose, red and watery eyes, followed by a characteristic skin rash. However, it can also lead to serious complications, including pneumonia, brain inflammation (encephalitis), blindness and death. It can also weaken the immune system for months after infection.
PAHO expects the US, Mexico and Bolivia to submit plans outlining how they plan to interrupt transmission and strengthen measles vaccination and surveillance.
The organisation has called on countries across the Americas to achieve and maintain at least 95% coverage with both doses of the measles vaccine.
The MMR vaccine, which protects against measles, mumps and rubella, remains the most effective way to prevent measles.
© $2026 Times Horizon Private Limited